

BioLight Announces Closing of Joint Investment in IOptima Subsidiary

Tel-Aviv, Israel, December 29, 2015 – BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) (“BioLight” or the “Company”), an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today that following its announcement on November 25, 2015 of BioLight’s IOptima Ltd. subsidiary (“IOptima”) regarding entering into a joint financing agreement (the “Agreement”) with two Asia-based venture capital firms (the “New Investors”), according to which the New Investors will invest an aggregate amount of US\$6.0 million (the “Investment Amount”) in consideration for the issuance of approximately 29% of IOptima’s issued and outstanding shares (post investment), on December 28, 2015, all closing terms were completed and IOptima received the Investment Amount against said share issuance.

Upon said completion of the Agreement, BioLight holds approximately 71% of IOptima’s issued and outstanding shares.

IOptima is a developer of minimally invasive surgical ophthalmic devices. The company’s flagship product, IOptiMate™, is based on CO2 laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball. The IOptiMate procedure provides high efficacy and allows for substantial reductions in post-operative complications and use of eye drops compared with alternatives. Recent marketing efforts by IOptima have resulted in first sales of IOptiMate™ in Hong Kong, Poland, Hungary, Romania, Peru and Portugal with distribution agreements also being negotiated in additional countries.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.